{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.061","upperLimit":"0.322","value":"0.158"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"All grade 4-5 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv4.03 that are not resolved in accordance with treatment guidelines were counted. Rate is the proportion of treated participants experiencing at least one of these adverse events as defined during the time of observation.","dispersionType":"80% Confidence Interval","groups":[{"description":"Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.\n\nTremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.\n\nDurvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.","id":"OG000","title":"Tremelimumab + Durvalumab"}],"paramType":"NUMBER","populationDescription":"This analysis dataset is comprised of all eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"Toxicity is assessed from the time of first dose of study medication until the participant comes off study. The median of treatment duration is 1.91 months with range (0.00 months - 23.46 months).","title":"Grade 4-5 Treatment-related Toxicity Rate","type":"SECONDARY","unitOfMeasure":"proportion of paticipants"}